These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. All-trans retinoic acid exerts selective anti-FLT3-ITD acute myeloid leukemia efficacy through downregulating Chk1 kinase. Wang W; Jiang Z; Wang L; Wang A; Liu J; Chen C; Yu K; Zou F; Wang W; Liu J; Liu Q Cancer Lett; 2020 Mar; 473():130-138. PubMed ID: 31904486 [TBL] [Abstract][Full Text] [Related]
3. NFATc1 as a therapeutic target in FLT3-ITD-positive AML. Metzelder SK; Michel C; von Bonin M; Rehberger M; Hessmann E; Inselmann S; Solovey M; Wang Y; Sohlbach K; Brendel C; Stiewe T; Charles J; Ten Haaf A; Ellenrieder V; Neubauer A; Gattenlöhner S; Bornhäuser M; Burchert A Leukemia; 2015 Jul; 29(7):1470-7. PubMed ID: 25976987 [TBL] [Abstract][Full Text] [Related]
4. Prevalence of FMS-like tyrosine kinase 3/internal tandem duplication (FLT3/ITD+) in de novo acute myeloid leukemia patients categorized according to cytogenetic risk. Krum EA; Yamamoto M; Chauffaille Mde L Sao Paulo Med J; 2009 Jan; 127(1):23-7. PubMed ID: 19466291 [TBL] [Abstract][Full Text] [Related]
5. The protein tyrosine phosphatase, Shp2, positively contributes to FLT3-ITD-induced hematopoietic progenitor hyperproliferation and malignant disease in vivo. Nabinger SC; Li XJ; Ramdas B; He Y; Zhang X; Zeng L; Richine B; Bowling JD; Fukuda S; Goenka S; Liu Z; Feng GS; Yu M; Sandusky GE; Boswell HS; Zhang ZY; Kapur R; Chan RJ Leukemia; 2013 Feb; 27(2):398-408. PubMed ID: 23103841 [TBL] [Abstract][Full Text] [Related]
6. [Correlation of Fms-like tyrosine kinase 3 (FLT3) gene expression to FLT3/internal tandem duplication mutation in peripheral blood of acute myeloid leukemia.]. Xu B; Shi PC; Song XY; Tang JH; Zhou SY Ai Zheng; 2009 Jun; 28(6):632-6. PubMed ID: 19635202 [TBL] [Abstract][Full Text] [Related]
7. Over-expression of FoxM1 is associated with adverse prognosis and FLT3-ITD in acute myeloid leukemia. Liu LL; Zhang DH; Mao X; Zhang XH; Zhang B Biochem Biophys Res Commun; 2014 Mar; 446(1):280-5. PubMed ID: 24582753 [TBL] [Abstract][Full Text] [Related]
8. FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation. Yoshimoto G; Miyamoto T; Jabbarzadeh-Tabrizi S; Iino T; Rocnik JL; Kikushige Y; Mori Y; Shima T; Iwasaki H; Takenaka K; Nagafuji K; Mizuno S; Niiro H; Gilliland GD; Akashi K Blood; 2009 Dec; 114(24):5034-43. PubMed ID: 19808698 [TBL] [Abstract][Full Text] [Related]
9. Integrin alphavbeta3 enhances β-catenin signaling in acute myeloid leukemia harboring Fms-like tyrosine kinase-3 internal tandem duplication mutations: implications for microenvironment influence on sorafenib sensitivity. Yi H; Zeng D; Shen Z; Liao J; Wang X; Liu Y; Zhang X; Kong P Oncotarget; 2016 Jun; 7(26):40387-40397. PubMed ID: 27248172 [TBL] [Abstract][Full Text] [Related]
10. Association of the EGF-TM7 receptor CD97 expression with FLT3-ITD in acute myeloid leukemia. Wobus M; Bornhäuser M; Jacobi A; Kräter M; Otto O; Ortlepp C; Guck J; Ehninger G; Thiede C; Oelschlägel U Oncotarget; 2015 Nov; 6(36):38804-15. PubMed ID: 26462154 [TBL] [Abstract][Full Text] [Related]
11. Independent oncogenic and therapeutic significance of phosphatase PRL-3 in FLT3-ITD-negative acute myeloid leukemia. Qu S; Liu B; Guo X; Shi H; Zhou M; Li L; Yang S; Tong X; Wang H Cancer; 2014 Jul; 120(14):2130-41. PubMed ID: 24737397 [TBL] [Abstract][Full Text] [Related]
12. The prognosis predictive value of FMS-like tyrosine kinase 3-internal tandem duplications mutant allelic ratio (FLT3-ITD MR) in patients with acute myeloid leukemia detected by GeneScan. Lyu M; Liao H; Shuai X; Jin Y; Su J; Zheng Q Gene; 2020 Feb; 726():144195. PubMed ID: 31669649 [TBL] [Abstract][Full Text] [Related]
13. Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth. Weir MC; Hellwig S; Tan L; Liu Y; Gray NS; Smithgall TE PLoS One; 2017; 12(7):e0181178. PubMed ID: 28727840 [TBL] [Abstract][Full Text] [Related]
14. Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation. Marhäll A; Heidel F; Fischer T; Rönnstrand L Ann Hematol; 2018 May; 97(5):773-780. PubMed ID: 29372308 [TBL] [Abstract][Full Text] [Related]
15. Elevated frequencies of leukemic myeloid and plasmacytoid dendritic cells in acute myeloid leukemia with the FLT3 internal tandem duplication. Rickmann M; Krauter J; Stamer K; Heuser M; Salguero G; Mischak-Weissinger E; Ganser A; Stripecke R Ann Hematol; 2011 Sep; 90(9):1047-58. PubMed ID: 21520003 [TBL] [Abstract][Full Text] [Related]
16. The FLT3 internal tandem duplication mutation is a secondary target of the aurora B kinase inhibitor AZD1152-HQPA in acute myelogenous leukemia cells. Grundy M; Seedhouse C; Shang S; Richardson J; Russell N; Pallis M Mol Cancer Ther; 2010 Mar; 9(3):661-72. PubMed ID: 20159992 [TBL] [Abstract][Full Text] [Related]
17. A potential therapeutic target for FLT3-ITD AML: PIM1 kinase. Fathi AT; Arowojolu O; Swinnen I; Sato T; Rajkhowa T; Small D; Marmsater F; Robinson JE; Gross SD; Martinson M; Allen S; Kallan NC; Levis M Leuk Res; 2012 Feb; 36(2):224-31. PubMed ID: 21802138 [TBL] [Abstract][Full Text] [Related]
18. Targeting CHK1 inhibits cell proliferation in FLT3-ITD positive acute myeloid leukemia. Yuan LL; Green A; David L; Dozier C; Récher C; Didier C; Tamburini J; Manenti S Leuk Res; 2014 Nov; 38(11):1342-9. PubMed ID: 25281057 [TBL] [Abstract][Full Text] [Related]
19. FMS-like tyrosine kinase 3 internal tandem duplication and the patterns of its gene sequence in 207 Chinese patients with de novo acute myeloid leukemia. Zhong L; Jia YQ; Meng WT; Ni X Arch Pathol Lab Med; 2012 Jan; 136(1):84-9. PubMed ID: 22208491 [TBL] [Abstract][Full Text] [Related]
20. Medium-sized FLT3 internal tandem duplications confer worse prognosis than short and long duplications in a non-elderly acute myeloid leukemia cohort. Koszarska M; Meggyesi N; Bors A; Batai A; Csacsovszki O; Lehoczky E; Adam E; Kozma A; Lovas N; Sipos A; Krahling T; Dolgos J; Remenyi P; Fekete S; Masszi T; Tordai A; Andrikovics H Leuk Lymphoma; 2014 Jul; 55(7):1510-7. PubMed ID: 24090502 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]